Comparison of Terlipressin, Somatostatin, and Octreotide for Control of Variceal Bleeding (NCT00966355) | Clinical Trial Compass
CompletedPhase 4
Comparison of Terlipressin, Somatostatin, and Octreotide for Control of Variceal Bleeding
South Korea1,034 participantsStarted 2006-09
Plain-language summary
This study is performed to compare the efficacy of terlipressin, somatostatin, and octreotide in patients with variceal bleeding for the control of variceal bleeding in combination with endoscopic therapy.
Who can participate
Age range16 Years – 75 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* liver cirrhosis
* age between 16 and 75 years
* Patients who have upper GI bleeding symptoms (hematemesis or melena) within 24 hours before enrollment
* Patients whose systolic blood pressure \<100 mmHg or pulse rate \>100/min at the enrollment
* Patients who were not performed endoscopic or pharmacologic therapy for varices
* Signed informed consent
Exclusion Criteria:
* Pregnancy
* Positive anti-HIV Ab
* A history of severe side-effects or contraindications to study drugs
* Severe cardiovascular diseases: acute myocardial infarction, A-V block, congestive heart failure, ischemic heart disease, hypertension (systolic blood pressure \>170 mmHg or diastolic pressure \>100 mmHg)
* Chronic renal failure
* Hepatocellular carcinoma with protal vein thrombosis
* Coexisting malignancy except hepatocellular carcinoma
What they're measuring
1
5-day Treatment Failure (Failure to Control Bleeding, Rebleeding, or Death)